

Ravulizumab for treating atypical haemolytic uraemic syndrome

Information for the public

Published: 23 June 2021

www.nice.org.uk

Ravulizumab (Ultomiris) is available on the NHS as a possible treatment for atypical haemolytic uraemic syndrome in people weighing 10 kg or more if:

- they have not had a drug called a complement inhibitor before or
- the disease has responded to at least 3 months of eculizumab treatment.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [aHUS Alliance Global Action](#), 07305 220135, info@ahusallianceaction.org
- [Kidney Research UK](#), 0300 303 1100

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4157-5